知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

103 records (took 0.038 seconds)

    Lipid-Based Antigens and T-Cell Receptors on NK Cells
    93.
    发明申请
    Lipid-Based Antigens and T-Cell Receptors on NK Cells 审中-公开

    公开(公告)号：US20200283531A1

    公开(公告)日：2020-09-10

    申请号：US16753330

    申请日：2018-10-04

    Applicant: NantCell, Inc.

    Inventor： Kayvan Niazi ,  Marcos Sixto ,  Annie Shin ,  Phil Liu

    IPC: C07K16/28 ,  A61K35/17 ,  C12N5/0783 ,  A61K39/39 ,  A61K9/00

    Abstract: Compositions, methods and uses of genetically modified NK cells to elicit immune response against cells infected with microorganisms are presented. In some embodiments, NK cells can be genetically modified with a recombinant nucleic acid that includes a segment encoding an extracellular single-chain variant fragment that specifically binds a CD1-lipid antigen complex and another segment encoding an intracellular activation domain, and a linker between those segments. In other embodiments, the NK cells can be genetically modified with a recombinant nucleic acid that includes a segment encoding an a chain T cell receptor and a β chain T cell receptor, and another segment encoding at least a portion of CD3δ and at least a portion of CD3γ. The genetically modified NK cells can be administered to the patient infected with microorganism to trigger immune response specific to the cells infected with the microorganism.

    Multimodal Vector for Dendritic Cell Infection
    99.
    发明申请
    Multimodal Vector for Dendritic Cell Infection 有权

    公开(公告)号：US20210198689A1

    公开(公告)日：2021-07-01

    申请号：US16081014

    申请日：2017-03-20

    Applicant: Nant Holdings IP, LLC ,  NantCell, Inc.

    Inventor： Patrick Soon-Shiong ,  Kayvan Niazi ,  Shahrooz Rabizadeh

    IPC: C12N15/86 ,  C07K14/705

    Abstract: Recombinant viruses and viral nucleic acids are contemplated that provide to the infected cell various regulatory molecules that stimulate T-cell and NK-cell activity and that suppress inhibition of T-cell and NK-cell activity. Most preferably, the virus and viral nucleic acid will further include a human cancer-associated sequence, and especially a sequence that encodes a plurality of cancer associated antigens, cancer specific antigens, and/or patient and tumor specific neoantigens. Especially preferred regulatory molecules include CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), CD11 (LFA-1), and an inhibitor of CTLA-4.

    Multivalent Antigens Stimulating TH1 and TH2
    100.
    发明申请
    Multivalent Antigens Stimulating TH1 and TH2 审中-公开

    公开(公告)号：US20200331976A1

    公开(公告)日：2020-10-22

    申请号：US16753272

    申请日：2018-10-04

    Applicant: NANTCELL, INC.

    Inventor： Patrick Soon-Shiong ,  Kayvan Niazi

    IPC: C07K14/47 ,  C07K14/74 ,  C12N15/86 ,  A61K48/00 ,  A61K39/00

    Abstract: Compositions, methods, and uses of recombinant nucleic acids to elicit Th1- or Th2-biased immune responses in an individual are presented. In some embodiments, the nucleic acid includes a first nucleic acid segment encoding a MHC-II trafficking signal and a second nucleic acid segment encoding a polytope peptide and a Th1-specific polarizing epitope or a Th2-specific polarizing epitope. Optionally, the Th1-specific polarizing epitope or the Th2-specific polarizing epitope is part of the polytope peptide. The recombinant nucleic acid can be inserted in a viral, bacterial, or yeast expression vector so that the recombinant protein encoded by the recombinant nucleic acid can be expressed in an antigen presenting cell of an individual to elicit Th1- or Th2-biased immune response in the individual.

Patent Agency Ranking